United States Healthcare Equipment & Supplies

Myriad Genetics Inc (MYGN)

Track

In the last 90 days, Myriad Genetics Inc. saw two insider buy transactions totaling $227,481.5. Notably, President and CEO Raha Samraat S. purchased shares worth $199,844. This activity occurred after the company's last earnings report, which missed expectations by 28.57%. The stock has experienced a 16.0% decline over the past 90 days.
Stock chart
Ticker: MYGN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Bisaro Paul
1 purchase — total 100,000 USD
Buy 14 May 2026
Value US$3,816,574.02 | Price 148.90 | Shares 45,258
Buy 9 Mar 2026
Value US$2,454,922.28 | Price 481.03 | Shares 19,580
Buy 27 Feb 2026
Value US$223,728.00 | Price 4.66 | Shares 48,000
Buy 26 Feb 2026
Value US$242,104.82 | Price 4.80 | Shares 50,407
Buy 25 Feb 2026
Value US$28,889.60 | Price 4.74 | Shares 6,100
Proposed sale 11 Oct 2024
Value US$343,950.00 | Price 22.93 | Shares 15,000
Planned sale 11 Oct 2024
Value US$343,950.00 | Price 22.93 | Shares 15,000
Planned sale 11 Sep 2024
Value US$400,800.00 | Price 26.72 | Shares 15,000
Proposed sale 11 Sep 2024
Value US$400,800.00 | Price 26.72 | Shares 15,000
Sale 11 Sep 2024
Value US$54,961.20 | Price 26.17 | Shares 2,100
Proposed sale 11 Sep 2024
Value US$54,960.57 | Price 26.17 | Shares 2,100
Proposed sale 10 Sep 2024
Value US$270,000.00 | Price 27.00 | Shares 10,000
Sale 9 Sep 2024
Value US$270,520.00 | Price 27.05 | Shares 10,000
Planned sale 3 Sep 2024
Value US$1,285,851.35 | Price 27.95 | Shares 46,012
Proposed sale 3 Sep 2024
Value US$1,297,078.28 | Price 28.19 | Shares 46,012
Proposed sale 21 Aug 2024
Value US$321,019.33 | Price 27.82 | Shares 11,538
Sale 21 Aug 2024
Value US$320,987.16 | Price 27.82 | Shares 11,538
Planned sale 19 Aug 2024
Value US$210,075.00 | Price 28.01 | Shares 7,500
Proposed sale 19 Aug 2024
Value US$210,075.00 | Price 28.01 | Shares 7,500
Proposed sale 4 Jun 2024
Value US$83,525.40 | Price 22.05 | Shares 3,788
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-14 2026-05-14 B Purchase
2.2
Bisaro Paul
Non-Executive Director
45,258 -28.4%
148.90
US$3,816,574 		45,258 -28.4% 148.90 US$3,816,574
2026-03-09 2026-03-09 B Purchase
0.9
Raha Samraat S.

President and CEO

Executive Director
19,580 +14.4%
481.03
US$2,454,922 		19,580 +14.4% 481.03 US$2,454,922
2026-02-27 2026-02-27 B Purchase
3.7
Phanstiel S. Louise
Non-Executive Director
61,840 +14.9%
488.52
US$1,789,972 		61,840 +14.9% 488.52 US$1,789,972
2026-02-27 2026-02-26 B Purchase
3.7
Phanstiel S. Louise
Non-Executive Director
50,407 +27.5%
4.80
US$242,105 		50,407 +27.5% 4.80 US$242,105
2026-02-27 2026-02-25 B Purchase
3.7
Phanstiel S. Louise
Non-Executive Director
6,100 +3.4%
4.74
US$28,890 		6,100 +3.4% 4.74 US$28,890
2024-10-11 2024-10-11 PrS Proposed sale
2.3
DIAZ PAUL J

Officer; Director

Executive Director
15,000
22.93
US$343,950 		15,000 22.93 US$343,950
2024-10-11 2024-10-11 PlS Planned sale
2.3
DIAZ PAUL J

President and CEO

Executive Director
15,000 -1.5%
22.93
US$343,950 		15,000 -1.5% 22.93 US$343,950
2024-09-12 2024-09-11 PlS Planned sale
2.3
DIAZ PAUL J

President and CEO

Executive Director
15,000 -1.5%
26.72
US$400,800 		15,000 -1.5% 26.72 US$400,800
2024-09-12 2024-09-11 S Sale
3.2
Muzzey Dale

Chief Scientific Officer

Officer
2,100 -1.9%
26.17
US$54,961 		2,100 -1.9% 26.17 US$54,961
2024-09-11 2024-09-11 PrS Proposed sale
3.2
Muzzey Dale

Officer

Officer
2,100
26.17
US$54,961 		2,100 26.17 US$54,961
2024-09-11 2024-09-11 PrS Proposed sale
2.3
DIAZ PAUL J

Officer; Director

Executive Director
15,000
26.72
US$400,800 		15,000 26.72 US$400,800
2024-09-09 2024-09-10 PrS Proposed sale
3.2
Dreismann Heinrich

Director

Non-Executive Director
10,000
27.00
US$270,000 		10,000 27.00 US$270,000
2024-09-09 2024-09-09 S Sale
3.2
Dreismann Heinrich
Non-Executive Director
10,000 -7.6%
27.05
US$270,520 		10,000 -7.6% 27.05 US$270,520
2024-09-04 2024-09-03 PlS Planned sale
1.1
Reitan Colleen F
Non-Executive Director
46,012 -52.0%
27.95
US$1,285,851 		46,012 -52.0% 27.95 US$1,285,851
2024-09-03 2024-09-03 PrS Proposed sale
1.1
Reitan Colleen F

Director

Non-Executive Director
46,012
28.19
US$1,297,078 		46,012 28.19 US$1,297,078
2024-09-16 2024-08-21 PrS Proposed sale
3.0
Ancona Margaret

Officer

Officer
11,538
27.82
US$321,019 		11,538 27.82 US$321,019
2024-08-23 2024-08-21 S Sale
3.0
Ancona Margaret

SVP, Chief of Staff

Officer
11,538 -12.7%
27.82
US$320,987 		11,538 -12.7% 27.82 US$320,987
2024-08-20 2024-08-19 PlS Planned sale
Kumar Rashmi
Non-Executive Director
7,500 -8.8%
28.01
US$210,075 		7,500 -8.8% 28.01 US$210,075
2024-08-19 2024-08-19 PrS Proposed sale
Kumar Rashmi

Director

Non-Executive Director
7,500
28.01
US$210,075 		7,500 28.01 US$210,075
2024-06-04 2024-06-04 PrS Proposed sale
SPIEGELMAN DANIEL K

Director

Non-Executive Director
3,788
22.05
US$83,525 		3,788 22.05 US$83,525
Explore more

More insider trading research around Myriad Genetics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Healthcare Services companies with insider activity
More Healthcare Equipment & Supplies companies with insider activity
Insider trading in North America